These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8186502)

  • 21. Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis.
    Latcha S; Hong S; Gibbons N; Kohn N; Mattana J
    Nephrol Dial Transplant; 2008 Oct; 23(10):3295-301. PubMed ID: 18443211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noninfectious complications of peritoneal dialysis: implications for patient and technique survival.
    McCormick BB; Bargman JM
    J Am Soc Nephrol; 2007 Dec; 18(12):3023-5. PubMed ID: 18003770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of nutritional status, dialysis adequacy, and residual renal function on the response to hepatitis B vaccination in peritoneal dialysis patients.
    Dacko C; Holley JL
    Adv Perit Dial; 1996; 12():315-7. PubMed ID: 8865927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hyperparathyroidism--why is it crucial to control serum phosphate?
    Brancaccio D; Gallieni M; Cozzolino M
    Nephrol Dial Transplant; 1996 Mar; 11(3):420-3. PubMed ID: 8671808
    [No Abstract]   [Full Text] [Related]  

  • 25. [Peritoneal dialysis in cirrhotic patients].
    De Vecchi AF
    G Ital Nefrol; 2009; 26(2):215-24. PubMed ID: 19382077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanding indications for dialysis.
    Port FK
    Int J Artif Organs; 1979 Mar; 2(2):47-8. PubMed ID: 468392
    [No Abstract]   [Full Text] [Related]  

  • 27. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients.
    Oh KH; Moon JY; Oh J; Kim SG; Hwang YH; Kim S; Lee JS; Ahn C
    Nephrol Dial Transplant; 2008 Jul; 23(7):2356-64. PubMed ID: 18178604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of cytokine measurements during in vitro and clinical haemodialysis.
    Pereira BJ
    Nephrol Dial Transplant; 1995; 10 Suppl 10():18-26. PubMed ID: 8825428
    [No Abstract]   [Full Text] [Related]  

  • 29. [Uremic toxins].
    Vanholder R
    Nephrologie; 2003; 24(7):373-6. PubMed ID: 14650749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereoselective protein binding of ketoprofen: effect of albumin concentration and of the biological system.
    Dubois N; Lapicque F; Abiteboul M; Netter P
    Chirality; 1993; 5(3):126-34. PubMed ID: 8338722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent peritoneal dialysis catheter exit-site leak in a patient receiving maintenance immunosuppression with sirolimus.
    Perl J; Jassal SV; Bargman JM
    Clin Transplant; 2008; 22(5):672-3. PubMed ID: 18435788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver support by extracorporeal blood purification: a clinical observation.
    Stange J; Mitzner SR; Klammt S; Freytag J; Peszynski P; Loock J; Hickstein H; Korten G; Schmidt R; Hentschel J; Schulz M; Löhr M; Liebe S; Schareck W; Hopt UT
    Liver Transpl; 2000 Sep; 6(5):603-13. PubMed ID: 10980060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On call. I am 58-year-old diabetic. I've had my PSA checked every year since I turned 50, but I'm now on kidney dialysis. Will dialysis change my PSA results?
    Simon HB
    Harv Mens Health Watch; 2001 Jun; 5(11):8. PubMed ID: 11439279
    [No Abstract]   [Full Text] [Related]  

  • 34. A bench to bedside view of uremic toxins.
    Vanholder R; Baurmeister U; Brunet P; Cohen G; Glorieux G; Jankowski J;
    J Am Soc Nephrol; 2008 May; 19(5):863-70. PubMed ID: 18287557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone.
    Elder G; Faull R; Branley P; Hawley C;
    Nephrology (Carlton); 2006 Apr; 11 Suppl 1():S230-61. PubMed ID: 16684078
    [No Abstract]   [Full Text] [Related]  

  • 36. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ultimate salt war? Uraemic toxins are all that count in dialysis patients.
    Vanholder R
    Nephrol Dial Transplant; 2012 Jan; 27(1):62-6. PubMed ID: 22287703
    [No Abstract]   [Full Text] [Related]  

  • 38. Serum middle molecules in uremia.
    Buzio C; Manari A; Calderini C; Montagna G; Migone L
    Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
    [No Abstract]   [Full Text] [Related]  

  • 39. Mathematical formulation of the dialysis index for middle molecules, D1(MM).
    Milutinovic J; Babb AL; Eschbach JW; Follette WC; Graefe U; Strand MJ; Scribner BH
    Artif Organs; 1978 Feb; 2(1):51-4. PubMed ID: 687021
    [No Abstract]   [Full Text] [Related]  

  • 40. [Study of toxic activity of blood in uremia].
    Shumakov VI; Gabriélian NI; Shcherbaneva OI; Dmitriev AA; Mogireva IA
    Ter Arkh; 1980; 52(4):62-4. PubMed ID: 7404340
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.